HMC
AZN icon

Harbert Management Corporation’s AstraZeneca AZN Stock Holding History

Harbert Management Corporation’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-105,000
Closed -$6.23M – 24
2013
Q4 		$6.23M Sell
105,000
-70,000
-40% -$3.8M 5.18% 6
2013
Q3 		$9.09M Buy
+175,000
New +$8.79M 4.95% 5

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Harbert Management Corporation's AZN Position: Q1 2014 in Review

Harbert Management Corporation sold out of AstraZeneca (AZN) in Q1 2014, closing a stake of 105,000 shares — an estimated $6.23M sold.

Harbert Management Corporation first reported a position in AZN in Q3 2013 and held it in 2 quarters. The position peaked at $9.09M in Q3 2013. 387 funds tracked by Wall St. Rank hold AZN as of Q1 2014.

  • Harbert Management Corporation reported no remaining AstraZeneca position as of Q1 2014 after selling out during the quarter.
  • Harbert Management Corporation sold 105,000 AstraZeneca shares in Q1 2014, an estimated $6.23M.
  • Harbert Management Corporation first reported a position in AstraZeneca in Q3 2013 and held it in 2 quarters.
  • Harbert Management Corporation's AstraZeneca position peaked at $9.09M in Q3 2013.
  • 387 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2014.

Based on Harbert Management Corporation's 13F filing for Q1 2014, filed 15 May 2014.